SOST (Sclerostin) variants and mutations
SOST (also known as Sclerostin) is a human protein-coding gene encoding a sclerostin protein. It restrains bone formation by inhibiting canonical Wnt signaling in osteoblast-lineage cells. Loss-of-function variants cause sclerosteosis or van Buchem disease with very high bone mass, while therapeutic neutralization increases bone formation in osteoporosis. This analysis covers 707 SOST variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes sclerosteosis 1, craniodiaphyseal dysplasia, and hyperostosis corticalis generalisata. Example SOST variants include Q2*, L3F, and P4L.
Variant analysis overview
- Gene: SOST
- Protein: Sclerostin
- UniProt accession: Q9BQB4
- Organism: Homo sapiens
- Variants analyzed: 707
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 270 unspecified-consequence records; 2 stop lost; 1 stop retained variant; 124 synonymous variants; 270 missense variants; 19 frameshift variants; 20 stop-gained variants; 2 in-frame deletions; 1 splice-region variants; 2 substitution
- Prediction scores: 671 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: sclerosteosis 1, craniodiaphyseal dysplasia, hyperostosis corticalis generalisata, osteoporosis, sclerosteosis, postmenopausal osteoporosis, bone fracture, myocardial infarction, osteogenesis imperfecta, bone disorder, heart disorder, anorexia nervosa.
Protein structure and variant hotspots
- Protein features: 1 domains; 2 post-translational modification sites.
- Structural context: 430 variants have structural context.
- PTM context: 5 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable SOST variants
Examples include Q2*, L3F, P4L, L5V, A6V, C8G, L9F, V10I. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q2* (p.Gln2Ter), ExAC rs769839504, gnomAD rs769839504, CADD 37.00
- L3F (p.Leu3Phe), rs745735992, NCI-TCGA Cosmic COSV5701, ExAC rs745735992, TOPMed rs745735992, REVEL 0.22, CADD 20.30, Variant assessed as somatic; moderate impact.
- P4L (p.Pro4Leu), gnomAD rs1477850027, REVEL 0.19, CADD 22.40
- L5V (p.Leu5Val), gnomAD rs1974161107, REVEL 0.22, CADD 15.70
- A6V (p.Ala6Val), rs781149929, ClinGen CA8592906, ClinVar RCV002802977, ExAC rs781149929, REVEL 0.12, CADD 19.20, Uncertain significance, Inborn genetic diseases
- C8G (p.Cys8Gly), TOPMed rs1974160884
- L9F (p.Leu9Phe), gnomAD rs769369803, REVEL 0.36, CADD 21.60, Uncertain significance, Inborn genetic diseases
- V10I (p.Val10Ile), rs17882143, ClinGen CA8592903, ClinVar RCV000360798, ClinVar RCV002056602, REVEL 0.12, CADD 0.19, Benign, not provided; Sclerosteosis 1
- V14A (p.Val14Ala), TOPMed rs1380461935, gnomAD rs1380461935, REVEL 0.26, CADD 22.50
- V14I (p.Val14Ile), ExAC rs765162616, gnomAD rs765162616, REVEL 0.10, CADD 4.66
- H15P (p.His15Pro), 1000Genomes rs528251296, ExAC rs528251296, gnomAD rs528251296, REVEL 0.48, CADD 16.80
- H15R (p.His15Arg), 1000Genomes rs528251296, ExAC rs528251296, gnomAD rs528251296, REVEL 0.15, CADD 13.50
- H15Y (p.His15Tyr), ExAC rs755487430, TOPMed rs755487430, gnomAD rs755487430, REVEL 0.28, CADD 16.40
- T16A (p.Thr16Ala), gnomAD rs1439063195, REVEL 0.11, CADD 0.06
- A17T (p.Ala17Thr), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- A17V (p.Ala17Val), gnomAD rs1363534429
- F18C (p.Phe18Cys), NCI-TCGA TCGA novel, REVEL 0.22, CADD 21.30, Variant assessed as somatic; moderate impact.
- R19C (p.Arg19Cys), TOPMed rs772369267, gnomAD rs772369267, REVEL 0.20, CADD 9.68
- R19H (p.Arg19His), rs199514554, ClinGen CA8592895, ClinVar RCV001125281, ClinVar RCV002070043, REVEL 0.14, CADD 0.55, Likely benign, Sclerosteosis 1; not provided
- V20A (p.Val20Ala), rs375589560, ClinGen CA8592894, ClinVar RCV002769695, ESP rs375589560, REVEL 0.11, CADD 5.84, Uncertain significance, Inborn genetic diseases
- V21L (p.Val21Leu), rs387907169, ClinGen CA399703409, ClinVar RCV000024298, UniProt VAR 065766, AlphaMissense 0.11, MetaLR 0.35, Pathogenic, Craniodiaphyseal dysplasia, autosomal dominant
- V21M (p.Val21Met), rs387907169, ClinGen CA129828, ClinVar RCV000024297, ClinVar RCV003398567, AlphaMissense 0.11, MetaLR 0.35, Likely pathogenic, SOST-related disorder; Craniodiaphyseal dysplasia, autosomal dominant
- E22D (p.Glu22Asp), ExAC rs775073017, NCI-TCGA Cosmic COSV5701, REVEL 0.25, CADD 18.60, Variant assessed as somatic; moderate impact.
- Q24* (p.Gln24Ter), rs387906320, ClinGen CA253289, ClinVar RCV000005049, ClinVar RCV005089173, CADD 36.00, Pathogenic
- Q24H (p.Gln24His), ExAC rs745824050, TOPMed rs745824050, gnomAD rs745824050
- Q24L (p.Gln24Leu), rs146848252, ClinGen CA8592891, ClinVar RCV002651941, 1000Genomes rs146848252, REVEL 0.28, CADD 23.00, Uncertain significance, Inborn genetic diseases
- G25E (p.Gly25Glu), rs776670653, ClinGen CA8592889, ClinVar RCV003378839, 1000Genomes rs776670653, REVEL 0.69, CADD 25.20, Uncertain significance, Inborn genetic diseases
- Q27* (p.Gln27Ter), rs2154590473, ClinGen CA399703324, ClinVar RCV001843443, Ensembl rs2154590473, CADD 36.00, Sclerosteosis 1
- Q27E (p.Gln27Glu), rs762683331, []
- A28V (p.Ala28Val), rs770960308, NCI-TCGA Cosmic COSV5701, ExAC rs770960308, TOPMed rs770960308, REVEL 0.24, CADD 20.70, Variant assessed as somatic; moderate impact.
- N31S (p.Asn31Ser), ExAC rs777424828, gnomAD rs777424828, REVEL 0.71, CADD 25.80
- D32E (p.Asp32Glu), rs1249296225, TOPMed rs1249296225, gnomAD rs1249296225, NCI-TCGA Cosmic COSV5701, REVEL 0.63, CADD 22.50, Variant assessed as somatic; moderate impact.
- D32Y (p.Asp32Tyr), NCI-TCGA Cosmic COSV1000, REVEL 0.89, CADD 26.80, Variant assessed as somatic; moderate impact.
- A33V (p.Ala33Val), ExAC rs748258858, gnomAD rs748258858, REVEL 0.74, CADD 27.40
- T34M (p.Thr34Met), rs200581535, 1000Genomes rs200581535, ESP rs200581535, ExAC rs200581535, REVEL 0.80, CADD 28.10, Variant assessed as somatic; moderate impact.
- E35K (p.Glu35Lys), TOPMed rs1974158843
- E35V (p.Glu35Val), Ensembl rs1974158785, REVEL 0.83, CADD 29.20
- I37T (p.Ile37Thr), Ensembl rs1974158689
- P38S (p.Pro38Ser), ESP rs373660644, ExAC rs373660644, TOPMed rs373660644, gnomAD rs373660644, REVEL 0.43, CADD 24.20
- P38T (p.Pro38Thr), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- E39K (p.Glu39Lys), ExAC rs762683331, TOPMed rs762683331, gnomAD rs762683331, REVEL 0.21, CADD 20.90, Uncertain significance, Inborn genetic diseases
- E39Q (p.Glu39Gln), ExAC rs762683331, TOPMed rs762683331, gnomAD rs762683331, REVEL 0.18, CADD 18.70
- L40H (p.Leu40His), ExAC rs774959099, gnomAD rs774959099, REVEL 0.24, CADD 23.40
- G41R (p.Gly41Arg), rs574411567, NCI-TCGA Cosmic COSV5701, 1000Genomes rs574411567, ExAC rs574411567, REVEL 0.17, CADD 12.30, Uncertain significance, Inborn genetic diseases
- E42D (p.Glu42Asp), ESP rs139822050, ExAC rs139822050, TOPMed rs139822050, gnomAD rs139822050
- Y43S (p.Tyr43Ser), Ensembl rs1598296941
- P44L (p.Pro44Leu), gnomAD rs1375948495, REVEL 0.24, CADD 21.50
- E45K (p.Glu45Lys), ExAC rs773071580, gnomAD rs773071580, REVEL 0.08, CADD 15.70
- P47Q (p.Pro47Gln), TOPMed rs1428033627, gnomAD rs1428033627, REVEL 0.30, CADD 20.60
- P48L (p.Pro48Leu), rs779039644, ClinGen CA8592863, ClinVar RCV001122500, ExAC rs779039644, REVEL 0.10, CADD 16.20, Uncertain significance, Sclerosteosis 1
- P48Q (p.Pro48Gln), ExAC rs779039644, TOPMed rs779039644, gnomAD rs779039644, REVEL 0.09, CADD 14.50, Uncertain significance
- P48S (p.Pro48Ser), NCI-TCGA TCGA novel, REVEL 0.17, CADD 15.20, Variant assessed as somatic; moderate impact.
- L50R (p.Leu50Arg), rs2508693316, ClinGen CA399702980, ClinVar RCV003366736, Uncertain significance, Inborn genetic diseases
- L50V (p.Leu50Val), 1000Genomes rs559177656, ExAC rs559177656, TOPMed rs559177656, gnomAD rs559177656, REVEL 0.22, CADD 20.30
- N52D (p.Asn52Asp), gnomAD rs1344864833
- N52K (p.Asn52Lys), TOPMed rs914981653, REVEL 0.35, CADD 22.60
- N53K (p.Asn53Lys), TOPMed rs1449266973, gnomAD rs1449266973, REVEL 0.56, CADD 26.00
- N53S (p.Asn53Ser), TOPMed rs1974157026
- N53del, rs758741179, []
- T55S (p.Thr55Ser), TOPMed rs1053399949, gnomAD rs1053399949, REVEL 0.42, CADD 23.60
- M56V (p.Met56Val), NCI-TCGA Cosmic COSV5701, Variant assessed as somatic; moderate impact.
- R58Q (p.Arg58Gln), ESP rs141856582, ExAC rs141856582, REVEL 0.18, CADD 21.60
- R58W (p.Arg58Trp), rs750840300, NCI-TCGA Cosmic COSV5701, ExAC rs750840300, TOPMed rs750840300, REVEL 0.64, CADD 29.70, Variant assessed as somatic; moderate impact.
- A59V (p.Ala59Val), rs541123476, NCI-TCGA Cosmic COSV1000, 1000Genomes rs541123476, ExAC rs541123476, REVEL 0.72, CADD 28.30, Variant assessed as somatic; moderate impact.
- E60K (p.Glu60Lys), gnomAD rs1286080574, REVEL 0.12, CADD 18.90
- N61D (p.Asn61Asp), gnomAD rs1370224367, REVEL 0.32, CADD 23.80
- G62E (p.Gly62Glu), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- G62R (p.Gly62Arg), rs372515234, ClinGen CA8592851, ClinVar RCV001924193, ClinVar RCV002560479, REVEL 0.75, CADD 26.80, Uncertain significance, not provided; Inborn genetic diseases
- G63R (p.Gly63Arg), gnomAD rs1356126797, REVEL 0.75, CADD 24.60
- R64Q (p.Arg64Gln), rs760682674, ClinGen CA8592849, NCI-TCGA Cosmic COSV1000, ClinVar RCV000728031, REVEL 0.67, CADD 27.20, Uncertain significance, not provided
- R64W (p.Arg64Trp), rs765929030, ClinGen CA8592850, ClinVar RCV002747202, ExAC rs765929030, REVEL 0.65, CADD 23.80, Uncertain significance, Inborn genetic diseases
- P65H (p.Pro65His), ESP rs147448439, ExAC rs147448439, TOPMed rs147448439, gnomAD rs147448439
- H67Q (p.His67Gln), TOPMed rs1330217415, gnomAD rs1330217415, REVEL 0.06, CADD 17.50
- H67Y (p.His67Tyr), TOPMed rs1974155825, gnomAD rs1974155825, REVEL 0.19, CADD 20.60
- H68Q (p.His68Gln), ESP rs143755073, ExAC rs143755073, TOPMed rs143755073, gnomAD rs143755073, REVEL 0.10, CADD 14.60
- P69H (p.Pro69His), TOPMed rs1261726802, REVEL 0.28, CADD 23.10
- P69S (p.Pro69Ser), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- T72N (p.Thr72Asn), rs2508693141, ClinGen CA399702767, ClinVar RCV002754636, REVEL 0.14, CADD 20.10, Uncertain significance, Inborn genetic diseases
- D74N (p.Asp74Asn), gnomAD rs1182524882, REVEL 0.19, CADD 27.60
- D74E (p.Asp74Glu), gnomAD 17-43755762-G-T, REVEL 0.04, CADD 17.10
- D74D (p.Asp74Asp), rs1375600998, gnomAD 17-43755762-G-A, CADD 9.88
- V75A (p.Val75Ala), gnomAD rs1405992033, REVEL 0.10, CADD 0.06
- V75G (p.Val75Gly), gnomAD rs1405992033
- V75M (p.Val75Met), ExAC rs774141032, TOPMed rs774141032, gnomAD rs774141032, REVEL 0.11, CADD 13.10
- p.Val75 Tyr78del, gnomAD 17-43755749-TGTAC, CADD 22.10
- V75V (p.Val75Val), gnomAD 17-43755759-C-T, CADD 4.48
- V75E (p.Val75Glu), gnomAD 17-43755760-A-T, REVEL 0.17, CADD 0.39
- V75L (p.Val75Leu), gnomAD 17-43755761-C-A, REVEL 0.10, CADD 8.11
- S76S (p.Ser76Ser), gnomAD 17-43755756-G-T, CADD 7.51
- S76F (p.Ser76Phe), gnomAD 17-43755757-G-A, REVEL 0.42, CADD 28.00
- S76C (p.Ser76Cys), gnomAD 17-43755757-G-C, REVEL 0.37, CADD 27.30
- S76Y (p.Ser76Tyr), gnomAD 17-43755757-G-T, REVEL 0.39, CADD 26.80
- S76P (p.Ser76Pro), gnomAD 17-43755758-A-G, REVEL 0.49, CADD 26.60
- E77K (p.Glu77Lys), ExAC rs768384322, TOPMed rs768384322, gnomAD rs768384322, REVEL 0.39, CADD 24.80
- E77D (p.Glu77Asp), gnomAD 17-43755753-C-A, REVEL 0.21, CADD 18.30
- E77E (p.Glu77Glu), gnomAD 17-43755753-C-T, CADD 11.60
- E77G (p.Glu77Gly), gnomAD 17-43755754-T-C, REVEL 0.28, CADD 23.70
- E77V (p.Glu77Val), gnomAD 17-43755754-T-A, REVEL 0.47, CADD 25.20
- E77A (p.Glu77Ala), gnomAD 17-43755754-T-G, REVEL 0.28, CADD 24.50
- E77* (p.Glu77Ter), gnomAD 17-43755755-C-A, CADD 37.00
- Y78S (p.Tyr78Ser), NCI-TCGA Cosmic COSV5701, Variant assessed as somatic; moderate impact.
- Y78* (p.Tyr78Ter), gnomAD 17-43755750-G-T, CADD 38.00
- Y78Y (p.Tyr78Tyr), rs763188625, gnomAD 17-43755750-G-A, CADD 12.60
- Y78C (p.Tyr78Cys), gnomAD 17-43755751-T-C, REVEL 0.51, CADD 25.10
- Y78F (p.Tyr78Phe), gnomAD 17-43755751-T-A, REVEL 0.14, CADD 20.50
- Y78H (p.Tyr78His), gnomAD 17-43755752-A-G, REVEL 0.40, CADD 25.50
- S79R (p.Ser79Arg), gnomAD 17-43755747-G-T, REVEL 0.66, CADD 27.60
- S79S (p.Ser79Ser), gnomAD 17-43755747-G-A, CADD 14.50
- S79N (p.Ser79Asn), gnomAD 17-43755748-C-T, REVEL 0.47, CADD 24.60
- S79I (p.Ser79Ile), gnomAD 17-43755748-C-A, REVEL 0.80, CADD 29.50
- S79G (p.Ser79Gly), gnomAD 17-43755749-T-C, REVEL 0.34, CADD 22.90
- C80C (p.Cys80Cys), gnomAD 17-43755744-G-A, CADD 14.40
- C80* (p.Cys80Ter), gnomAD 17-43755744-G-T, CADD 38.00
- C80Y (p.Cys80Tyr), gnomAD 17-43755745-C-T, REVEL 0.90, CADD 31.00
- C80F (p.Cys80Phe), gnomAD 17-43755745-C-A, REVEL 0.88, CADD 31.00
- R81C (p.Arg81Cys), gnomAD rs1248654294, REVEL 0.58, CADD 26.10
- R81R (p.Arg81Arg), gnomAD 17-43755741-G-A, CADD 8.47
- R81H (p.Arg81His), gnomAD 17-43755742-C-T, REVEL 0.69, CADD 29.70
- R81L (p.Arg81Leu), gnomAD 17-43755742-C-A, REVEL 0.71, CADD 25.40
- R81S (p.Arg81Ser), gnomAD 17-43755743-G-T, REVEL 0.70, CADD 27.90
- E82G (p.Glu82Gly), gnomAD rs1974123745, REVEL 0.81, CADD 32.00
- E82K (p.Glu82Lys), rs1482371714, gnomAD rs1482371714, REVEL 0.80, CADD 31.00, Variant assessed as somatic; moderate impact.
- E82E (p.Glu82Glu), rs1974123695, gnomAD 17-43755738-C-T, CADD 13.70
- E82D (p.Glu82Asp), gnomAD 17-43755738-C-A, REVEL 0.66, CADD 24.70
- E82* (p.Glu82Ter), gnomAD 17-43755740-C-A, CADD 37.00
- L83L (p.Leu83Leu), gnomAD 17-43755735-C-T, CADD 14.10
- L83Q (p.Leu83Gln), gnomAD 17-43755736-A-T, REVEL 0.82, CADD 32.00
- L83M (p.Leu83Met), gnomAD 17-43755737-G-T, REVEL 0.41, CADD 23.10
- H84Y (p.His84Tyr), ExAC rs775651591, gnomAD rs775651591, REVEL 0.23, CADD 23.40
- H84Q (p.His84Gln), gnomAD 17-43755732-G-T, REVEL 0.18, CADD 22.90
- H84H (p.His84His), rs930477861, gnomAD 17-43755732-G-A, CADD 12.70
- H84N (p.His84Asn), gnomAD 17-43755734-G-T, REVEL 0.28, CADD 24.90
- F85L (p.Phe85Leu), Ensembl rs921804354, REVEL 0.17, CADD 23.70
- F85F (p.Phe85Phe), gnomAD 17-43755729-G-A, CADD 15.50
- F85Y (p.Phe85Tyr), gnomAD 17-43755730-A-T, REVEL 0.12, CADD 22.90
- F85S (p.Phe85Ser), gnomAD 17-43755730-A-G, REVEL 0.12, CADD 22.10
- T86P (p.Thr86Pro), Ensembl rs1598296166
- T86T (p.Thr86Thr), gnomAD 17-43755726-G-T, CADD 13.60
- T86N (p.Thr86Asn), gnomAD 17-43755727-G-T, REVEL 0.72, CADD 28.90
- T86I (p.Thr86Ile), gnomAD 17-43755727-G-A, REVEL 0.85, CADD 31.00
- T86A (p.Thr86Ala), gnomAD 17-43755728-T-C, REVEL 0.70, CADD 24.40
- R87H (p.Arg87His), TOPMed rs1974123446, REVEL 0.38, CADD 24.40
- R87R (p.Arg87Arg), gnomAD 17-43755723-G-A, CADD 15.30
- R87L (p.Arg87Leu), gnomAD 17-43755724-C-A, REVEL 0.57, CADD 24.60
- R87C (p.Arg87Cys), gnomAD 17-43755725-G-A, REVEL 0.70, CADD 32.00
- R87G (p.Arg87Gly), gnomAD 17-43755725-G-C, REVEL 0.71, CADD 26.20
- R87S (p.Arg87Ser), gnomAD 17-43755725-G-T, REVEL 0.61, CADD 25.40
- Y88* (p.Tyr88Ter), gnomAD 17-43755720-G-T, CADD 35.00
- Y88Y (p.Tyr88Tyr), rs769974877, gnomAD 17-43755720-G-A, CADD 11.10
- Y88C (p.Tyr88Cys), gnomAD 17-43755721-T-C, REVEL 0.58, CADD 26.40
- Y88H (p.Tyr88His), gnomAD 17-43755722-A-G, REVEL 0.35, CADD 24.40
- V89M (p.Val89Met), rs867579353, TOPMed rs867579353, gnomAD rs867579353, REVEL 0.54, CADD 25.20, Variant assessed as somatic; moderate impact.
- V89V (p.Val89Val), gnomAD 17-43755717-C-T, CADD 14.90
- V89A (p.Val89Ala), gnomAD 17-43755718-A-G, REVEL 0.70, CADD 30.00
- V89L (p.Val89Leu), gnomAD 17-43755719-C-G, REVEL 0.11, CADD 21.80
- T90T (p.Thr90Thr), gnomAD 17-43755714-G-A, CADD 5.05
- T90N (p.Thr90Asn), gnomAD 17-43755715-G-T, REVEL 0.37, CADD 24.20
- D91D (p.Asp91Asp), gnomAD 17-43755711-A-G, CADD 12.90
- D91E (p.Asp91Glu), gnomAD 17-43755711-A-T, REVEL 0.23, MetaLR 0.29
- D91G (p.Asp91Gly), gnomAD 17-43755712-T-C, REVEL 0.72, CADD 31.00
- D91N (p.Asp91Asn), gnomAD 17-43755713-C-T, REVEL 0.53, CADD 31.00
- D91Y (p.Asp91Tyr), gnomAD 17-43755713-C-A, REVEL 0.76, CADD 31.00
- D91M (p.Asp91Met), gnomAD 17-43755713-CG-C, CADD 15.80
- G92E (p.Gly92Glu), TOPMed rs1974123349, REVEL 0.87, CADD 29.40
- G92G (p.Gly92Gly), gnomAD 17-43755708-C-T, CADD 13.50
- G92V (p.Gly92Val), gnomAD 17-43755709-C-A, REVEL 0.87, MetaLR 0.76
- G92A (p.Gly92Ala), gnomAD 17-43755709-C-G, REVEL 0.80, MetaLR 0.62
- G92R (p.Gly92Arg), gnomAD 17-43755710-C-T, REVEL 0.76, MetaLR 0.56
- P93L (p.Pro93Leu), TOPMed rs1159168815, gnomAD rs1159168815, REVEL 0.17, CADD 13.20
- P93R (p.Pro93Arg), TOPMed rs1159168815, gnomAD rs1159168815, REVEL 0.15, CADD 12.80
- P93P (p.Pro93Pro), gnomAD 17-43755705-C-A, CADD 8.58
- P93Q (p.Pro93Gln), gnomAD 17-43755706-G-T, REVEL 0.09, MetaLR 0.15
- P93T (p.Pro93Thr), gnomAD 17-43755707-G-T, REVEL 0.23, MetaLR 0.33
- P93S (p.Pro93Ser), gnomAD 17-43755707-G-A, REVEL 0.21, MetaLR 0.27
- P93A (p.Pro93Ala), gnomAD 17-43755707-G-C, REVEL 0.28, MetaLR 0.27
- C94C (p.Cys94Cys), gnomAD 17-43755702-G-A, CADD 15.10
- C94* (p.Cys94Ter), gnomAD 17-43755702-G-T, CADD 37.00
- C94Y (p.Cys94Tyr), gnomAD 17-43755703-C-T, REVEL 0.90, MetaLR 0.73
- C94F (p.Cys94Phe), gnomAD 17-43755703-C-A, REVEL 0.90, MetaLR 0.73
- C94R (p.Cys94Arg), gnomAD 17-43755704-A-G, REVEL 0.90, MetaLR 0.72
Public SOST analysis runs
- SOST analysis run — SOST (707 variants) — completed 2026-08-21